Blog: A Bumpy, Slow Transformation to Biomaterials?

Although it is widely accepted that one day cheap oil will run out, even in a world of seemingly generous government funding some biomaterial technology providers are struggling to deliver the solutions while maintaining profitability.   Verenium (Cambridge, MA), a biotech firm, could be one such company: Laurence Alexander, an analyst with investment bank Jefferies and Company (New York), in a recent report, downgraded forecast 2010 earnings per share for Verenium from $0.35 to a loss of $2.2. Alexander doesn’t opt for a positive stance in 2011...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers